Drugs / autologous tumor cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00136422 | Jan 2000 → Mar 2006 | acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00912418 | May 2000 → Sep 2002 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous tumor cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00912418 ↗ |
| Modality | Vaccine | “new investigational acute myeloblastic leukemia (AML) vaccine” NCT00136422 ↗ |